-34.5%
PINS vs MRNA
+27.0%
-61.5%
-65.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -9.2% | -3.4% | -5.9% | -9.1% |
| 7D | -13.9% | -10.1% | -3.8% | -13.4% |
| 30D | -25.0% | +126.7% | -151.7% | -30.9% |
| 3M | -16.6% | +184.1% | -200.7% | -25.8% |
| 6M | -7.0% | +143.3% | -150.3% | -15.8% |
| YTD | -29.4% | +359.9% | -389.2% | -42.3% |
| 1Y | -49.9% | +454.2% | -504.1% | -60.6% |
| All | -34.5% | +27.0% | -61.5% | -44.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling